CoChat

Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium

Open access
Pettersen, Erik O., Ebbesen, Peter, Gieling, Roben G., Williams, Kaye J., Dubois, Ludwig, Lambin, Philippe, Ward, Carol, Meehan, James, Kunkler, Ian H., Langdon, Simon P., Ree, Anne H., Flatmark, Kjersti, Lyng, Heidi, Calzada, Maria J., Peso, Luis del, Landazuri, Manuel O., Görlach, Agnes, Flamm, Hubert, Kieninger, Jochen, Urban, Gerald, Weltin, Andreas, Singleton, Dean C., Haider, Syed, Buffa, Francesca M., Harris, Adrian L., Scozzafava, Andrea, Supuran, Claudiu T., Moser, Isabella, Jobst, Gerhard, Busk, Morten, Toustrup, Kasper, Overgaard, Jens, Alsner, Jan, Pouyssegur, Jacques, Chiche, Johanna, Mazure, Nathalie, Marchiq, Ibtissam, Parks, Scott, Ahmed, Afshan, Ashcroft, Margaret, Pastorekova, Silvia, Cao, Yihai, Rouschop, Kasper M., Wouters, Brad G., Koritzinsky, Marianne, Mujcic, Hilda, Cojocari, Dan · 2015 · Journal of Enzyme Inhibition and Medicinal Chemistry
Cited by 115

The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.

Abstract

The hypoxic areas of solid cancers represent a negative prognostic factor irrespective of which treatment modality is chosen for the patient. Still, after almost 80 years of focus on the problems created by hypoxia in solid tumours, we still largely lack methods to deal efficiently with these treatment-resistant cells. The consequences of this lack may be serious for many patients: Not only is there a negative correlation between the hypoxic fraction in tumours and the outcome of radiotherapy as well as many types of chemotherapy, a correlation has been shown between the hypoxic fraction in tumours and cancer metastasis. Thus, on a fundamental basis the great variety of problems related to hypoxia in cancer treatment has to do with the broad range of functions oxygen (and lack of oxygen) have in cells and tissues. Therefore, activation-deactivation of oxygen-regulated cascades related to metabolism or external signalling are important areas for the identification of mechanisms as potential targets for hypoxia-specific treatment. Also the chemistry related to reactive oxygen radicals (ROS) and the biological handling of ROS are part of the problem complex. The problem is further complicated by the great variety in oxygen concentrations found in tissues. For tumour hypoxia to be used as a marker for individualisation of treatment there is a need for non-invasive methods to measure oxygen routinely in patient tumours. A large-scale collaborative EU-financed project 2009-2014 denoted METOXIA has studied all the mentioned aspects of hypoxia with the aim of selecting potential targets for new hypoxia-specific therapy and develop the first stage of tests for this therapy. A new non-invasive PET-imaging method based on the 2-nitroimidazole [(18)F]-HX4 was found to be promising in a clinical trial on NSCLC patients. New preclinical models for testing of the metastatic potential of cells were developed, both in vitro (2D as well as 3D models) and in mice (orthotopic grafting). Low density quantitative real-time polymerase chain reaction (qPCR)-based assays were developed measuring multiple hypoxia-responsive markers in parallel to identify tumour hypoxia-related patterns of gene expression. As possible targets for new therapy two main regulatory cascades were prioritised: The hypoxia-inducible-factor (HIF)-regulated cascades operating at moderate to weak hypoxia (<1% O(2)), and the unfolded protein response (UPR) activated by endoplasmatic reticulum (ER) stress and operating at more severe hypoxia (<0.2%). The prioritised targets were the HIF-regulated proteins carbonic anhydrase IX (CAIX), the lactate transporter MCT4 and the PERK/eIF2α/ATF4-arm of the UPR. The METOXIA project has developed patented compounds targeting CAIX with a preclinical documented effect. Since hypoxia-specific treatments alone are not curative they will have to be combined with traditional anti-cancer therapy to eradicate the aerobic cancer cell population as well.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3109/14756366.2014.966704

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 65 references

Cited by

See all 115

Metadata

Authors
Pettersen, E. O., Ebbesen, P., Gieling, R. G., Williams, K. J., Dubois, L., Lambin, P., Ward, C., Meehan, J., Kunkler, I. H., Langdon, S. P., Ree, A. H., Flatmark, K., Lyng, H., Calzada, M. J., Peso, L. D., Landazuri, M. O., Görlach, A., Flamm, H., Kieninger, J., Urban, G., Weltin, A., Singleton, D. C., Haider, S., Buffa, F. M., Harris, A. L., Scozzafava, A., Supuran, C. T., Moser, I., Jobst, G., Busk, M., Toustrup, K., Overgaard, J., Alsner, J., Pouyssegur, J., Chiche, J., Mazure, N., Marchiq, I., Parks, S., Ahmed, A., Ashcroft, M., Pastorekova, S., Cao, Y., Rouschop, K. M., Wouters, B. G., Koritzinsky, M., Mujcic, H., & Cojocari, D.
Venue
Journal of Enzyme Inhibition and Medicinal Chemistry
Published
2014-10-27
Volume
30
Issue
5
Pages
689-721
ISSN
  • 1475-6366 (ISSN-L)
  • 1475-6374
OpenAlex
W2104898929
Cited by
115
References
65
FWCI
4.08
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium. https://app.cochat.ai/papers/10.3109/14756366.2014.966704
The paper
Pettersen, E. O., Ebbesen, P., Gieling, R. G., Williams, K. J., Dubois, L., Lambin, P., Ward, C., Meehan, J., Kunkler, I. H., Langdon, S. P., Ree, A. H., Flatmark, K., Lyng, H., Calzada, M. J., Peso, L. D., Landazuri, M. O., Görlach, A., Flamm, H., Kieninger, J., . . . Cojocari, D. (2015). Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium. Journal of Enzyme Inhibition and Medicinal Chemistry. https://doi.org/10.3109/14756366.2014.966704

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.